# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
− Approval Based on Results from Positive, Global, Phase 3 FRESCO-2 Trial− FRUZAQLA (fruquintinib) is the First Novel Targeted ...
- Financial Timeshttps://www.ft.com/content/360751cb-7a22-48e0-9b00-6a30ff41dcfe
US stock markets mixed as investors analyze economic data & Fed comments. Jobless claims fall, housing stats & permits ...
-Reuters
US stock markets closed higher on Tuesday with S&P 500 and Nasdaq reaching record highs. Nvidia became world's most val...